PRÉVENTION Le dépistage du cancer colorectal est volontaire - mais les médecins le recommandent fortement. Prof. Dr. med. Christoph Beglinger Specialist for Gastroenterology u. Internal Medicine Cancer Colorectal - Dépistage : il y a maintenant trois options pour la prévention. La Suisse est à la traîne dans le dépistage du cancer colorectal selon une comparaison internationale. Seuls
Le cancer du côlon représente la deuxième cause de mortalité par cancer chez les hommes et les femmes en Europe1. Le nombre de cas devrait encore augmenter ces vingt prochaines années en raison du vieillissement de la population. Mais s’il est diagnostiqué suffisamment tôt, le cancer du côlon a un taux élevé de guérison et
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold
Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with
Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with
Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with